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action, cellular accumulation, ribonucleotide reductase inhibition, ER stress, apoptosis, cell cycle 
Abstract
Six morpholine-(iso)thiosemicarbazone hybrids HL1‒HL6 and their Cu(II) complexes with good-to-
moderate solubility and stability in water were synthesized and characterized. Cu(II) complexes 
[Cu(L1‒6)Cl] (1‒6) formed weak dimeric associates in the solid state, which did not remain intact in 
solution as evidenced by ESI-MS. The lead proligands and Cu(II) complexes displayed higher 
antiproliferative activity in cancer cells than Triapine. In addition, complexes 2‒5 were found to 
specifically inhibit the growth of Gram-positive bacteria S. aureus with MIC50 values at 2 to 5 µg/mL. 
Insights into the processes controlling intracellular accumulation and mechanism of action were 
investigated for 2 and 5, including the role of ribonucleotide reductase (RNR) inhibition, endoplasmic 
reticulum (ER) stress induction and regulation of other cancer signaling pathways. Their ability to 
moderately inhibit R2 RNR protein in the presence of DTT is likely related to Fe chelating properties of 
the proligands liberated upon reduction. 
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3Introduction
Progress in modern anticancer therapy has led to significant improvements in survival rates of cancer 
patients. However, even though more patients achieve remission nowadays, their life-span often remains 
short.1 One of the major causes of cancer death is the malignant process itself, which is associated with 
extensive formation of metastases, but it is not commonly mentioned that a significant number of 
immunocompromised cancer patients die due to infections, such as pneumonia and peritonitis.2 Despite 
that cancer patients are very prone to develop infections during chemotherapy, their preventive antibiotic 
treatment is hampered by additional adverse effects.3 However, recent clinical evidence demonstrated 
that benefits of antibiotic prophylaxis of cancer patients outweighed its risks.4 The simultaneous 
suppression of pathogenic microorganisms during anticancer chemotherapy could not only interrupt or 
abolish tumor growth but eventually protect cancer patients from infection. Hence, the development of 
novel drugs which exhibit dual anticancer and antibacterial properties in comparable concentration range 
would affect the malignant process and simultaneously decrease the risk of patients’ death due to 
infection, febrile neutropenia and bacteraemia.
Both cancer and bacterial cells share similar properties, such as high rate of proliferation, rapid 
adjustment and quick spreading within the host and aggressive disease progression.5 In order to sustain 
such rapid proliferation, cancer and bacterial cells have to support DNA replication and production of 
RNA by increasing de novo nucleotide synthesis. Ribonucleotide reductase (RNR) is the key enzyme 
that catalyzes the reduction of ribonucleotides to their corresponding deoxyribonucleotides, thereby 
initiating DNA synthesis or repair, making it an important biomolecular target for drugs with anticancer 
and antibacterial properties.6,7 RNR consists of a large subunit (NrdA or R1), which contains the 
allosteric site that regulates and catalyzes substrate reduction, and a small subunit (NrdB or R2) with the 
diferric-tyrosyl radical cofactor, essential for the catalytic activity of the RNR enzyme. Small molecules, 
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4that can sequester Fe(III) from the dinuclear metal center and/or scavenge the tyrosyl radical, inhibit R2 
activity, thereby preventing de novo DNA synthesis in cancer cells and bacteria.
α-N-heterocyclic thiosemicarbazones (TSCs) are excellent transition metal chelators and have a broad 
range of activities, including anticancer and antibacterial properties, which are believed to be at least 
partially due to their RNR inhibition.8 To date, several TSC compounds, namely 3-amino-2-
pyridinecarboxaldehyde thiosemicarbazone (Triapine),9,10,11 di-2-pyridylketone 4-cyclohexyl-4-methyl-
3-thiosemicarbazone (DpC)12,13 and (E)-N´-(6,7-dihydroquinolin-8(5H)-ylidene)-4-(pyridine-2-
yl)piperazine-1-carbothiohydrazide (COTI-2)14 are undergoing phase I and II clinical trials against 
various types of cancer. The main caveat in the use of TSCs is their high toxicity which is reflected in a 
number of side-effects in clinical trials involving Triapine.9,10,11 Many studies have shown that Cu(II)-
TSC complexes often display better selectivity than their TSC proligands, which can be attributed to the 
induction of different intracellular signaling pathways.15
Despite advances in the design and synthesis of new TSCs and Cu(II)-TSC complexes over the years, 
these compounds are facing the problem of low aqueous solubility, thereby hampering their further 
development. Therefore, the synthesis of water-soluble and cytotoxic TSCs and Cu(II)-TSC complexes 
requires a thoughtful selection of the functional groups that can be attached at the TSC backbone without 
reducing their biological activity.16,17,18,19,20 With the aim to reach the optimal combination of aqueous 
solubility and high cytotoxicity, we designed new (iso)thiosemicarbazone-morpholine hybrids and their 
Cu(II) complexes. Notably, morpholine moiety was chosen since it confers excellent water solubility, 
which typically translates into an improved pharmacological effect. Additionally, morpholine 
derivatives possess a broad spectrum of biological activities, including anticancer and antibacterial 
therapeutic potential.21 For example, commercial anticancer drugs Aprepitant and Gefinitib, as well as 
antibacterial drugs Finafloxacin and Levofloxacin include a morpholine fragment in their structures.
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Chart 1. Line drawings of proligands HL1‒6 and Cu(II) complexes [Cu(L1‒6)Cl] (1‒6) reported in this work. All proligands 
and Cu(II) complexes, but HL3 and 2, were investigated by single crystal X-ray crystallography.
Herein we report on the synthesis of water-soluble proligands HL1‒6 and Cu(II) complexes 1‒6 (Chart 
1), which were characterized by analytical and various spectroscopic techniques. X-ray diffraction 
structures of HL1, HL2, HL3‒HL6 and 1, 3‒6 were established and solution equilibria studies for HL1 
and Cu(II) complex formation with HL1 by pH-potentiometry, UV‒vis, EPR and 1H NMR spectroscopy, 
as well as electrochemistry were performed. Antiproliferative activity against human ovarian cancer 
A2780 and cisplatin resistant A2780cis cell lines, non-cancerous HEK293 cell line, as well as 
antibacterial activity against Gram-positive (S. aureus) compared to Gram-negative bacteria (P. 
aeruginosa) were investigated and structure-activity relationships discussed. The processes controlling 
cellular accumulation of 2 were investigated. Preliminary insights into the mode of action of 2 and 5, 
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6including mouse R2 RNR inhibitory potential, studied by molecular modeling and tyrosyl radical 
quenching monitored by EPR spectroscopy, as well as by Western Blotting and flow cytometry are also 
presented. 
Results 
Synthesis and characterization of (iso)thiosemicarbazone-morpholine hybrids and their Cu(II) 
complexes. The 5-methylmorpholine-pyridine-2-carboxaldehyde H was prepared in seven steps as 
shown in Scheme 1 and the detailed synthesis is described in the Supporting Information. First pyridine-
2,5-dicarboxylic acid A was converted into diester B that was further reduced to the diol C. The latter 
was selectively oxidized with SeO2 to the aldehyde D. After protection of the aldehyde group the alcohol 
E was converted into the chloride F that was further reacted with morpholine to give species G. Finally, 
the hydrolysis of the methyl ester function in acidic conditions afforded the required aldehyde H for 
condensation reactions with thiosemicarbazide, 4N-dimethyl-3-thiosemicarbazide, 4N-pyrrolydinyl-3-
thiosemicarbazide, 4N-morpholinyl-3-thiosemicarbazide, 4N-phenyl-3-thiosemicarbazide and S-
methylisothiosemicarbazide hydroiodide to give the hybrids HL1‒6 (Scheme 1), respectively. One- and 
two-dimensional NMR spectra were in agreement with the proposed structures for HL1‒6, enabling the 
assignment of all 1H and 13C resonances. The ESI mass spectra recorded in a positive ion mode showed 
strong peaks corresponding to [M+H]+ and [M+Na]+ ions, respectively. The proligands HL1‒6 were 
reacted with Cu(II) chloride dihydrate and triethylamine in 1:1:1 mole ratio in methanol to give 
[Cu(L1‒6)Cl] (1‒6) in 35‒91% yields. Positive ion ESI mass spectra showed strong peaks attributed to 
[Cu(L1‒6)]+ ions. The structures of 1, 3‒6 were also established by single crystal X-ray diffraction (vide 
infra). 
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Scheme 1. Synthesis of 5-methylmorpholine-pyridine-2-carboxaldehyde. Reagents and conditions: (i) thionyl chloride, 
methanol, 0 °C → room temperature, 12 h;22 (ii) sodium borohydride, ethanol, acetone, potassium carbonate, chloroform, 0 
°C, 1 h → reflux, overnight;23 (iii) selenium dioxide, dioxane, water, 100 °C, 3 h;24 (iv) trimethyl orthoformate, 
methanesulfonic acid, methanol, reflux, 48 h; (v) thionyl chloride, dichloromethane, ‒80 °C → room temperature, overnight; 
(vi) moprholine, triethylamine, THF/CH2Cl2 1:1, 50 °C, overnight, purification by column chromatography; (vii) HCl, water, 
60 °C, overnight.
X-ray Crystallography. The results of X-ray diffraction studies of HL1, HL2 and HL4‒6 are shown in 
Figure S1, while those of [Cu(L1)Cl] (1), [Cu(L3)Cl] (3), [Cu(L4)Cl] (4), [Cu(L5)Cl] (5) and 
[Cu(L1)Cl(H2O)] (1´), [Cu(L6)Cl] (6) in Figures 1 and 2, respectively. Selected bond distances and 
bond angles are quoted in Tables S1 and S2. The proligands adopted different isomeric configurations 
in the solid state depending on substituents at the terminal nitrogen atom of the thiosemicarbazide moiety. 
Complexes 1, 3, 4 and 5 form dimeric associates as shown in Figure 1 (co-crystallized solvent was 
omitted for clarity). Each Cu(II) ion has a distorted square-planar coordination geometry. Intermolecular 
contacts supporting the dimeric associates in the crystals are of different nature in 1 and 3‒5, 
respectively. The presence of long intermolecular contacts Cu···Cl or Cu···Cl and Cu···S (see legend to 
Figure 1) provides evidence of weak association of complexes in dimers, which most probably dissociate 
in solution with formation of monomeric species. There was no evidence from ESI mass spectra on the 
presence of dimeric species in solution. 
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8Figure 1. ORTEP views of weak dimeric associates of (a) [Cu(L1)Cl] (1), (b), [Cu(L3)Cl] (3), (c) [Cu(L4)Cl]2 (4) and (d) 
[Cu(L5)Cl] (5). 
Moreover, HL1 reacts with CuCl2 in aqueous solution with formation of five-coordinate complex 
[Cu(L1)Cl(H2O)] (1´·2H2O) (Figure 2b). The monomeric square-planar complex [Cu(L6)Cl] forms an 
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9infinite chain via weak coordination of the morpholine oxygen atom of one complex to the Cu(II) atom 
of the next molecule as shown in Figure S2. The intermolecular Cu···O contact is of 2.603(3) Å.
Figure 2. ORTEP views of (a) [Cu(L1)Cl(H2O)] (1´) and (b) [Cu(L6)Cl] (6). 
Solution Chemistry. In order to establish the presence of isomers of the proligands in aqueous solution 
and proton dissociation processes, in which these can be involved solution equilibrium studies have been 
performed. Likewise, the solution speciation of the copper(II) complexes, as well as their stability have 
been investigated to elucidate the species, which is the most stable and abundant at physiological pH. 
The proligand HL1 (Chart 1) was chosen for the detailed solution equilibrium studies since it has the 
simplest structure and the best aqueous solubility among the proligands prepared. The presence of 
different isomers in solution was excluded by measurements of 1H NMR spectra in 10% D2O/90% H2O 
(Figure S3), which showed only one set of signals for the proligand in accordance to its low (C1) 
molecular symmetry. The proligand most probably adopts the E configuration found in the solid state 
(Figure S1). The same configuration was reported previously for the reference compound 2-
formylpyridine thiosemicarbazone in polar solvents.25 Proton dissociation processes were monitored in 
aqueous solution by pH-potentiometric and 1H NMR titrations and three pKa values were determined by 
both methods (Table S3). According to the obtained pKa values HL1 is mainly neutral (97% HL, 3% 
H2L+) at physiological pH (Figure S4). Inspection of 1H NMR spectra revealed stepwise deprotonation 
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10
of three functional groups in the following order: NpyridiniumH+ → NmorpholiniumH+ → NhydrazineH (Figure 
S3). 
The solution speciation of the Cu(II) complexes with HL1 was characterized by the combined use of 
pH-potentiometry, UV−vis spectrophotometry (via charge transfer (CT) and d-d bands) and EPR 
spectroscopy. The spectral changes (Table S4, Figures 3a and S5) in the UV and visible regions 
measured at 1:1 metal-to-ligand ratio show the high-extent formation of a Cu(II) complex already at 
strongly acidic pH values (e.g. pH 1) and its stepwise deprotonation by increasing the pH. At pH 7.4 the 
dominant species is [CuL]+ (Figure 3b). 
0.0
0.2
0.4
0.6
0.0
0.2
0.4
0.6
0.8
1.0
1 3 5 7 9 11
A
sorbance 
M
ol
ar
 fr
ac
tio
n
of
 L
pH
[CuLH2]3+
[CuLH]2+ [CuL]
+ [CuLH-1]
(B)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
240 290 340 390 440
A
bs
or
ba
nc
e
 / nm
3.79
1.11
9.56-11.60
6.37-7.48
(A)
Absorbance
(a) (b)
Figure 3. UV–vis spectra recorded for the Cu(II)–HL1 (1:1) system at various pH values (a), and concentration distribution 
curves and measured absorbance values at 346 nm (♦) and 440 nm (■) for the same system (b). {cCu(II) = clig = 121 µM; T = 
298 K; I = 0.10 M (KCl); l = 0.5 cm}. 
Due to the high stability of the Cu(II) complexes formed, the cumulative constant (logβ) for the [CuL]+ 
species (Table S4) was determined via EDTA displacement studies (Figure S6). Then the pKa and the 
logβ values for the other type of complexes ([CuLH2]3+, [CuLH]2+, [CuLH-1]) were computed using each 
method and data were in a fairly good agreement (Table S4). It is worth noting that formation of a bis-
ligand complex [CuL2] at ligand excess was also confirmed by the UV−vis CT and EPR titrations. The 
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11
d-d bands (Figure S5) recorded from pH 3.4 to 7.5 at 1:1 metal-to-ligand ratio revealed that the proton 
dissociation process of [CuLH]2+ → [CuL]+ is accompanied by rather weak spectral changes as most 
probably the non-coordinating morpholinium NH+ is deprotonating. In order to further characterize the 
coordination modes of the various complexes in solution EPR parameters (Table S5) obtained by the 
deconvolution of the recorded spectra (Figure S7) were analyzed. The isotropic g and A values of 
[CuLH]2+ and [CuL]+ are quite similar indicating the like coordination mode. 
Comparison of the EPR parameters of the Cu(II) complexes of HL1 with those of 2-formylpyridine 
thiosemicarbazone25 and Triapine26 permitted to conclude that in the [CuLH]2+ and [CuL]+ complexes a 
typical coordination mode via the Npyridyl,N,S− binding site is realized in accordance with the X-ray 
diffraction data. [CuLH2]3+ contains the diprotonated ligand in which the protons are attributed to the 
non-coordinating N2H and morpholinium NH+ moieties, while [CuLH-1] is most probably a mixed 
hydroxido complex [CuL(OH)] formed by the deprotonation of water molecule coordinated in the fourth 
equatorial position. At ligand excess besides the bis-ligand complex a minor dinuclear species 
[Cu2L3H]2+ was detected resulting in the weak exchange coupling between neighboring Cu(II) centers 
smearing out the expected hyperfine structure. 
Cu(II)-TSC complexes undergo quasi-reversible one-electron reduction at biologically accessible 
potentials. In order to assess the redox properties of 1‒6, detailed electrochemical and spectroscopic 
studies in various solvents were performed using cyclic voltammetry as well as EPR–
spectroelectrochemistry. Additionally, the UV‒vis spectra of 1‒5 were measured (Figure S8). 
Electrochemical and spectroscopic data are summarized in Table S6. Almost reversible one-electron 
cathodic reduction was observed for 1‒5 in DMSO with half-wave redox potentials from –0.77 V to –
0.81 V vs Fc+/Fc (for comparison from –0.13 V to –0.17 V vs NHE) (Table S6 and Figure S9). In 
general, the values of redox potentials of 1‒6 for the first reduction step decreased in the following rank 
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12
order (E1/2(5) > E1/2(2) = E1/2(3) = E1/2(4) > E1/2(1) > E1/2(6)). The second reduction step occurred at –
1.8 V vs Fc+/Fc (–1.16 V vs NHE) and was less reversible indicating a ligand based reduction. This was 
confirmed by the CVs of the corresponding proligands which exhibited the first reduction step at around 
–1.9 V vs Fc+/Fc (not shown). In aqueous solutions the reduction potentials shifted to the less negative 
values and reduction was less reversible as shown for 2 in Figure S10. Complex 6 exhibited different 
redox behavior with the lowest electrochemical reversibility and the most negative reduction potential 
of –0.86 V vs Fc+/Fc (–0.26 V vs NHE) (Figure S9c). Unlike the cathodic reduction, the anodic oxidation 
of 1‒6 was irreversible with potential values in the region from 0.4 to 0.8 V vs Fc+/Fc (0.68 V to 1.44 V 
vs NHE). Similar response was observed for the corresponding proligand HL2 (Figure S11), indicating 
ligand based oxidation in 2.
The biologically accessible reduction of Cu(II)-TSC complexes is Cu-centered. To investigate 
whether the biologically accessible reduction is metal-centered, the reversible one-electron reduction of 
5 was further studied by in situ UV‒vis-spectroelectrochemistry (Figure 4a). Upon cathodic reduction 
at the first reduction peak two isosbestic points at 389 and 325 nm were detected. The spectral changes 
of the S→Cu(II) charge transfer bands (~425 nm) clearly confirmed the reduction of Cu(II) to Cu(I). 
Additionally, upon voltammetric reverse scan, reoxidation and a nearly full recovery of the initial optical 
bands were observed, attesting the chemical reversibility of the cathodic reduction even at low scan rates 
(Figure 4). To confirm the involvement of Cu(II) in the reduction processes, in situ EPR electrochemistry 
of 1‒6 in nBu4NPF6/DMSO and water was performed, since metal-based reduction would result in the 
formation of EPR-silent Cu(I) species (Figure 4b). As can be seen for electrochemical reduction of 2 in 
nBu4NPF6/DMSO in the region of the first one–electron reduction step (see inset in Figure 4b), a 
significant decrease of EPR signal was observed in accord with the formation of diamagnetic Cu(I) d10 
complex. For aqueous solutions the reversibility was significantly reduced, implying a more complex 
mechanism involving the release of the proligand. However, by decreasing the scan rate and going to 
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the more positive potentials upon reverse scan, a partial recovery of the initial optical bands was also 
observed in aqueous solutions as shown for 2 in Figure S12. Thus, electrochemical data indicated a likely 
reduction of Cu(II)-TSC complexes to Cu(I) species with the subsequent release of the proligands. 
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Figure 4. Spectroelectrochemistry of 2 in nBu4NPF6/DMSO in the region of the first cathodic peak. (a) Potential dependence 
of UV‒vis spectra with respective cyclic voltammogram (Pt-microstructured honeycomb working electrode, scan rate v = 5 
mV s−1); (b) evolution of UV‒vis spectra in 2D projection in forward scan (Inset: EPR spectra measured at the first reduction 
peak using Pt mesh working electrode).
Lead TSCs and their Cu(II) complexes exhibited marked antiproliferative activity in a nanomolar 
concentration range. The in vitro anticancer activity of 1‒6 and their respective TSCs was determined 
in ovarian carcinoma cells (A2780 and A2780cisR) and non-cancerous human embryonic kidney cells 
(HEK293) by the colorimetric MTT assay with an exposure time of 72 h. The IC50 values for HL1‒HL6 
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and 1‒6 in comparison with Triapine, CuCl2, Cu-Triapine and cisplatin are listed in Tables 1 and 2, 
respectively, and concentration-effect curves are depicted in Figure S13. 
Table 1. Cytotoxicity of proligands HL1‒6 and their n-octanol/water distribution coefficients (logD7.4) 
Compound IC50 [μM]a logD7.4d
A2780 A2780cis RFb HEK293 SFc
HL1 7.6  1.9 13  1 1.7 9.1  1.7 1.2 +0.46  0.01
HL2 0.010  0.001 0.035  0.006 3.5 0.030  0.005 3.0 +0.51  0.02
HL3 0.008  0.002 0.028  0.006 3.5 0.022  0.005 2.8 +1.0  0.1
HL4 0.07  0.01 0.76  0.06 10.9 0.35  0.05 5.0 +0.37  0.04
HL5 0.31  0.08 1.1  0.2 3.5 0.67  0.06 2.2 ≥2
HL6 157  21 426  44 2.7 89  2 0.6 +0.84  0.01
Triapine 0.67  0.22 1.1  0.1 4.6 0.39  0.05 0.6 n.d.e
a 50% inhibitory concentrations (IC50) in human ovarian carcinoma cell lines A2780 and A2780cisR and human embryonic 
kidney cell line HEK293, determined by means of the MTT assay after 72 h exposure. Values are means ± standard deviations 
obtained from at least three independent experiments, bResistance Factor (RF) is determined as IC50 (A2780cisR)/IC50 (A2780), c 
Selectivity Factor (SF) is determined as IC50 (HEK293)/IC50 (A2780),  d Distribution coefficients between n-octanol and buffered 
aqueous solution determined at physiological pH by UV‒vis spectroscopy. Values are means ± standard deviations obtained 
from at least three independent experiments, e n.d. – not determined.
With the exception of HL1 and HL6, the proligands demonstrated marked antiproliferative activity in a 
submicromolar to nanomolar concentration range in both A2780 and A2780cisR cells. The efficacy of 
compounds HL2, HL3 and HL5 in cisplatin-resistant A2780cisR cells decreased by factor 3.5 in 
comparison to that in sensitive A2780 cells, whereas a 4.6- and 11-fold drop of activity was observed 
for Triapine and HL4, respectively. The activity of proligands HL1‒6 and Triapine increased in the 
following rank order HL6 < HL1 < Triapine < HL5 < HL4 << HL2  HL3 (Table 1).
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Table 2. Cytotoxicity of Cu(II)-TSC complexes 1‒6, CuCl2 and cisplatin and their n-octanol/water 
distribution coefficients (logD7.4) 
Compound IC50 [μM]a Cellular 
accumulation,d 
nmol Cu/
mg protein
logD7.4e
A2780 A2780cis HEK293 RFb SFc A2780
1 2.2  0.1 13  4 16  2 5.9 7.3 0.63  0.09 –0.81  0.04
2 0.012  0.002 0.030  0.003 0.032  0.008 2.5 2.7 3.9  0.6 +0.30  0.01
3 0.26  0.02 0.60  0.05 0.78  0.20 2.3 3.0 2.2  0.6 +0.86  0.02
4 0.08  0.01 0.26  0.04 0.24  0.02 3.3 3.0 3.2  0.7 +0.12  0.01
5 0.009  0.002 0.017  0.002 0.020  0.003 1.9 2.2 4.1  0.9 +1.49  0.06
6 43  3 62  6 72  0 1.4 1.7 0.47  0.08 –0.23  0.01
CuCl2 83  12 82  3 187  37 1.0 2.3 0.17  0.05 f n.d. g
Cu-Triapineh 1.3  0.1 29  0.3 n.d. 22.3 - n.d. n.d.
Cisplatin 0.44  0.13 4.6  0.3 n.d. 10.5 - - –2.30  0.79i
a 50% inhibitory concentrations (IC50) in human ovarian carcinoma cell lines A2780 and A2780cisR and human embryonic 
kidney cell line HEK293, determined by means of the MTT assay after exposure for 72 h. Values are means ± standard 
deviations obtained from at least three independent experiments, bResistance Factor (RF) is determined as IC50 (A2780cisR)/IC50 
(A2780),
 c Selectivity Factor (SF) is determined as IC50 (HEK293)/IC50 (A2780), d Cellular accumulation in A2780 cells, determined 
by ICP-MS after 24 h exposure at concentration of 1 μM. Values are means ± standard deviations obtained from at least three 
independent experiments, e Distribution coefficients between n-octanol and buffered aqueous solution determined at 
physiological pH by UV‒vis spectroscopy. Values are means ± standard deviations obtained from at least three independent 
experiments, f Cellular accumulation of CuCl2 was detected at concentration of 2.5 μM, g n.d. – not determined, h the IC50 
values (exposure for 72 h) were taken from the ref.. 27,i Log Po/w value was taken from the ref. 28.
As can be seen in Table 2, with the exception of 3, all Cu(II)-TSC complexes were equally or more 
cytotoxic than the respective proligands. The activity of complexes 1‒6 increased in the following order 
6 < 1 < 3 < 4 << 2 < 5, similar to the trend in electrochemical redox potentials for Cu-based reduction 
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step (Table S6). In order to compare the cytotoxicity of 1‒6 with that of [Cu(H2O)6]2+, A2780 cells were 
treated with aqueous solution of CuCl2. In agreement with the literature,29 CuCl2 revealed 
antiproliferative activity in the high micromolar range, in contrast to high activity of 1‒6, which should 
be regarded as individual entities with their own biological, pharmacokinetic and metabolic profiles. 
Complexes 1‒6 were up to ~50 times more cytotoxic than cisplatin in A2780 cells and up to ~270 times 
more cytotoxic in A2780cisR cells. Additionally, the differences in cytotoxicity of 1‒6 in A2780 and 
A2780cisR cells were significantly lower than for HL1‒HL6 and cisplatin, indicating high potential of 
Cu(II) complexes for the treatment of cisplatin-resistant tumors. The most active TSC proligands and 
their respective Cu(II) complexes were more selective towards A2780 cells over HEK293 cells; 
however, they did not show any selectivity towards A2780cisR cells over HEK293 cells. On the 
contrary, Triapine was significantly more cytotoxic towards non-cancerous HEK cells than A2780 or 
A2780cis cells.
Antiproliferative activity of Cu(II)-TSC complexes correlates with their cellular accumulation and 
lipophilicity. The ability of anticancer drugs to penetrate biological membranes, tissues and barriers 
underlies their biological, pharmacokinetic and metabolic properties. These properties can be predicted 
by calculating physicochemical characteristics of drug candidates using molecular descriptors.30 In order 
to estimate if the proligands HL1‒HL6 and corresponding Cu(II) complexes demonstrate drug-like 
properties, they were evaluated with main stream molecular descriptors, such as molecular weight 
(MW), number of hydrogen bond donors and acceptors (HBD/HBA), n-octanol-water partition 
coefficient (log P), polar surface area (PSA) and rotatable bonds (RB). The results are shown in Table 
S7 in the Supporting Information. Based on the calculated physicochemical parameters, we determined 
if novel compounds belonged to the drug-like chemical space, which is commonly defined by the well-
known Lipinski rule, or to the known drug space (KDS), which includes all small compounds in medical 
use.31 As can be seen from Table S7, all compounds fell within the boundaries of drug-like chemical 
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space with the exception of HL4 which demonstrated higher HBA value, referring to KDS space. Based 
on these results, novel compounds are expected to be sufficiently cell permeable. Following the 
calculations, we determined the lipophilicity of all compounds experimentally (logD7.4, Tables 2 and 3). 
It is known that cancer cells accumulate hydrophilic compounds to a smaller extent relative to 
hydrophobic compounds, thereby affecting their activity. Hence, the differences in the lipophilicity of 
compounds might be related to the observed trends in cytotoxicity of 1‒6. In general, with the exception 
of morpholine derivative HL4, proligands which were obtained by systematic substitution at the terminal 
thioamide nitrogen, demonstrated higher lipophilicity when compared to that of HL1. As expected, 
proligands were more lipophilic than the corresponding Cu(II) species, which are positively charged at 
physiological pH (Figure 3b). Among Cu(II)-TSC complexes, only the least cytotoxic complexes 1 and 
6, as well as cisplatin, demonstrated negative logD7.4 values, indicating their higher hydrophilicity. The 
lipophilicity of 2‒5 increased in the following order 4 < 2 < 3 < 5, and correlated well with their 
cytotoxicity in cancer cells, with the exception of 3. Subsequently, we determined the total cellular 
accumulation of Cu in A2780 cells by ICP-MS upon 24 h exposure to 1‒6 in comparison with CuCl2 
(Table 4). The IC50 values from MTT assays with 72 h drug exposure varied from nanomolar to high 
micromolar concentrations; therefore, in the cellular accumulation experiment cells were treated with 1 
μM of compounds of interest for 24 h to minimize cell detachment. The cellular accumulation of all 
Cu(II)-TSC complexes was significantly higher than for CuCl2, indicating the role of lipophilic TSC 
ligands in the delivery of the complexes into the cells. The accumulation increased in the order 6 < 1 < 
3 < 4 < 2 < 5. 
Cellular accumulation and efflux of Cu(II)-TSC complexes are energy- and/or temperature-
dependent processes. Dependence of cytotoxicity on lipophilicity of 1‒6 indicates that their cellular 
accumulation at least partially occurs via passive diffusion. In order to gain additional insights into the 
mechanisms controlling the accumulation of Cu(II)-TSC complexes, we investigated the effects of 
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temperature and various inhibitors on total cellular accumulation of 2 with the results shown in Figure 
5. A2780 cells were treated with 2 at 3 μM for 30, 60 and 120 min at 37 and 4 C and intracellular Cu 
content was measured by ICP-MS. Prolonged incubation at low temperatures may result in the changes 
in membrane fluidity, decreasing membrane permeability and restricting drug uptake;32 therefore, the 
shorter time point of 10 min was also included. The cellular accumulation of 2 dramatically decreased 
at low temperature even after 10 min treatment, indicating the involvement of active carrier-mediated 
transport or facilitated diffusion. Likewise, the decrease of cellular accumulation at low temperatures 
has been reported for both Cu(II)-TSC complexes and metal-free TSCs.33,34 To further clarify whether 
the uptake of 2 requires energy, the cellular ATP production was blocked by incubating cells in a saline 
solution (HBSS), resulting in total starvation and rapid reduction of intracellular ATP content, and/or by 
addition of oligomycin, leading to the inhibition of oxidative phosphorylation. 
Figure 5. Effects of temperature and inhibitors on the accumulation of 2 in A2780 cells. Intracellular content was determined 
by ICP-MS: a) A2780 cells were treated with 2 (3 μM) at 37 or 4 C for the indicated time periods. b) A2780 cells were pre-
treated with oligomycin (5 μM), and/or pre-incubated in HBSS for 1 h, or pre-treated with cycloheximide (100 μM) for 4 h 
and subsequently co-treated with 2 (3 μM) for 1 h. The presence of inhibitors did not show any effects on the intracellular 
Cu level of untreated A2780 cells (data not shown). Statistical analysis was performed by two-tailed T-test using GraphPad 
Prism software (GraphPad Software Inc., CA) with p < 0.05 considered as significant (* p < 0.05, ** p < 0.01). 
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When A2780 cells were pre-treated with 5 μM of oligomycin for 1 or 4 h and subsequently co-treated 
with 3 μM of 2, the intracellular Cu levels were not affected, even though the mitochondrial respiration 
of the cancer cells was successfully inhibited (data not shown). However, when A2780 cells were starved 
in HBSS for 1 h and subsequently treated with 3 μM of 2 for 1 h, an increase in intracellular Cu content 
was observed. Co-treatment of 2 with 5 μM of oligomycin in HBSS did not result in a further increase 
of intracellular Cu levels. The increase of Cu content in HBSS-starved cells might stem from the 
inhibition of energy-dependent efflux processes. In order to assess the role of proteins in both cellular 
accumulation and efflux of 2, A2780 cells were pre-treated with cycloheximide, which is a known 
inhibitor of protein synthesis. Significant increase of intracellular Cu content was observed, similar to 
HBSS starvation, providing further evidence for the involvement of protein-dependent efflux processes. 
Similar effects have been reported for related Cu(II)-TSC complexes.33 Accumulated data provide 
evidence that cellular accumulation of 2 occurs via carrier-facilitated diffusion, which might co-exist 
with passive permeation through the lipid bilayer.35 The efflux processes, however, are actively 
mediated by proteins and upon inhibition of protein synthesis or energy production a strong increase of 
intracellular Cu concentration was observed.  
Cu(II)-TSC complexes demonstrated high antibacterial activity against S. aureus in a comparable 
concentration range to ciprofloxacin. The antibacterial activity of HL1‒HL6 and 1‒6 on planktonic 
cells of P. aeruginosa and S. aureus was investigated by determination of MIC50 and MIC100 values 
(Table 3). Overall, compounds showed a higher antimicrobial activity against Gram-positive (S. aureus) 
compared to Gram-negative bacteria (P. aeruginosa). The highest activity against S. aureus was 
observed for 2‒5, which specifically inhibited its growth with MIC50 values ranging between 2 and 5 
µg/mL and completely abolished its growth at 10 µg/mL (MIC100). This activity is comparable but 
slightly lower that the antibacterial activity of a well-known benchmarked antibiotics ciprofloxacin 
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(CPX). On the contrary, P. aeruginosa exhibited high resistance to most of the compounds tested with 
the exception of HL2 and 2 with MIC50 values at 70 and 50 µg/mL, respectively. 
Table 3. Antibacterial activity of HL1‒6 and 1‒6a
S. aureus (g/mL) P. aeruginosa (g/mL)
MIC50 MIC100 MIC50 MIC100
HL1 100 >400 NA NA
HL2 10 400 50 100
HL3 10 300 100 NA
HL4 100 >400 NA NA
HL5 10 300 NA NA
HL6 NA NA NA NA
1 100 >500 NA NA
2 2 10 70 200
3 3 10 100 400
4 5 10 100 400
5 3 10 200 450
6 NA NA 200 NA
Ciprofloxacin 0.5 1 0.5 2
aSee experimental section for details. NA denotes no antibacterial activity detected (>500 µg/mL).
Compounds HL6 and 6 based on S-methylisothiosemicarbazide were completely devoid of antibacterial 
activity and no inhibition of bacterial growth was observed at the whole concentration range tested. 
Interestingly, metal-free thiosemicarbazones HL1‒HL5 displayed relatively low antibacterial activity 
(MIC100 > 300 μg/mL), which was significantly enhanced upon coordination to Cu(II). Subsequently, 
the mode of action of the most active compounds 2‒5 was evaluated in S. aureus and P. aeruginosa 
using the Live/Dead viability assay. As shown in Figure 6, compounds 2‒5 greatly reduced cell 
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replication, reflected by the lower number of cells compared to the untreated sample and high percentage 
of PI-stained cells, indicating compromised cell membrane allowing the penetration of propidium iodide 
and a bacteriostatic action of these compounds. 
Figure 6. Live/dead bacterial cells are shown by staining with green fluorescence indicating live cells and red fluorescence 
indicating dead cells.
TSCs and their Cu(II) complexes are located in a close proximity to the active site of mouse R2 
RNR protein. Next, the RNR inhibitory potential of the TSC proligands HL1‒HL6 and their 
corresponding Cu(II) complexes 1‒6 was investigated. The proligands HL1‒HL6 and Cu(II) complexes 
1‒6 were docked into the crystal structure of mouse R2 RNR subunit (PDBid:1W68)36 using GOLD 
software.37 To predict the binding of 1‒6, the GoldScore function was used and its parameters were 
modified to include Cu since they are not in GOLD’s database.38 The scoring functions are presented in 
Table S8. Overall, similar docking results were observed for all proligands and their Cu(II) complexes, 
suggesting a plausible binding to the mouse R2 protein. The compounds were deeply embedded into the 
pocket of the R2 subunit, close to the diferric center (Fe2O), and the enzymatically essential tyrosyl 
residue (Tyr177). The docked configuration of 5 in comparison with Triapine into the binding site is 
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shown in Figure 7. An overlap with Triapine was predicted, resulting in a partial reproduction of a 
hydrogen-bonding pattern (Figure S14, Table S8). 
Figure 7. The overlay of docked configurations of Cu(II) complex 5 (grey) and Triapine (green) in the binding site of the 
mouse R2 RNR protein (PDB ID: 1W68). The surface is rendered. Blue and brown depict hydrophilic and hydrophobic areas, 
respectively. 
Lead TSCs and their Cu(II) complexes cause moderate inhibition of a mouse R2 RNR protein in 
a reducing environment as a result of iron chelation. The effects of the most cytotoxic complexes 2 
and 5, and the corresponding proligands HL2 and HL5, on the mouse R2 tyrosyl radical were investigated 
by EPR spectroscopy at 30 K. The proligands and their  Cu(II) complexes were incubated with the mouse 
R2 RNR protein at 1:1 protein-to-compound mole ratio at 298 K in the presence or absence of the 
reducing agent dithiothreitol (DTT), and the time-dependent reduction of the tyrosyl radical was 
monitored.39 Tyrosyl radical reduction by the investigated compounds was observed only in the presence 
of DTT. Upon incubation with HL2, HL5 and 2, 5, 50% of tyrosyl radical was reduced within 90 s, after 
which no further reduction was observed (Figure S15). Since the diferric center of the mouse R2 protein 
is expected to be reduced upon addition of DTT,40,41 the ability of proligands HL2 and HL5 to form 
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stable Fe(II) complexes was investigated by monitoring these reactions by UV‒vis measurements in 
buffered aqueous solutions at pH 7.4. HL2 and HL5 (max = 312 and 320 nm, respectively) readily reacted 
with FeSO4·7H2O affording Fe(II) bis-ligand complexes (max = 373, 610 nm and max = 385, 645 nm, 
respectively) at both 1:1 and 1:2 Fe-to-ligand mole ratios. Additionally, the formation of Fe(III) 
complexes with the subsequent reduction by DTT was investigated (Figure S15). HL2 and HL5 reacted 
with FeCl3.6H2O (at 1:1 or 1:2 Fe-to-ligand mole ratios) to give [FeIII(L2)2]+ and [FeIII(L5)2]+ complexes 
(max = 378 nm, 612 nm and max = 386 nm, 635 nm, respectively). The formation of [FeIII(L5)2]+ species 
was confirmed by ESI-MS (Figure S16). The absorption spectra of reduced forms were almost identical 
to those of Fe(II) bis-ligand species, and to the previously reported spectra of other FeII-TSC 
complexes.42 
HL2 and 2 induced unfolded protein response (UPR), antioxidant defense and cell cycle 
perturbations. In order to get further insight into the mechanism of action of 2, Western Blotting of ER 
stress-related protein markers, namely IRE1α, CHOP, BiP/GRP78 and p-ERK, was performed (Figure 
8). When A2780 cells were treated with increasing concentrations of 2 for 24 h, the dose-dependent 
upregulation of IRE1α and CHOP proteins, decrease of ER stress chaperone BiP/GRP78, as well as 
phosphorylation of ERK were observed as a response to ER stress. To assess the effects of 2 on the cell 
cycle, we examined the expression of cyclin D1 and cyclin B1 which serve as cell cycle regulatory 
switches in actively proliferating cells and are required for cell cycle progression in G1 and G2 phases, 
respectively. Complex 2 displayed significant inhibition of cyclin D1 expression, indicating cell cycle 
arrest at G1/S phase, whereas no changes in cyclin B1 expression were detected. Subsequently, we 
compared the effects of 2 and the respective proligand HL2 on the expression of p-ERK1/2 and the 
marker of antioxidant defence NRF2. Both HL2 and 2 demonstrated phosphorylation of ERK1/2; 
however, the effects on NRF2 were markedly different. Whereas no increase of NRF2 expression was 
observed, when cells were treated with HL2, complex 2 induced increased expression of NRF2 even at 
Page 23 of 60
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
24
low concentration, indicating activated antioxidant defense, possibly as a result of ROS insult caused by 
Cu(II) reduction.  
Figure 8. Western Blot analysis of various proteins. A2780 cells were treated with increasing concentrations of proligand 
HL2 and complex 2 (corresponding to IC50 value from MTT experiment with exposure time of 72 h) for 24 h. Total lysates 
were isolated and examined by Western Blot. Actin was used as a loading control. 
HL2 and 2 induced dose-dependent apoptosis accompanied by PARP cleavage and XIAP 
inhibition. To elucidate if observed cytotoxicity of new compounds described in this study was a result 
of apoptosis induction, we conducted Annexin V/PI apoptosis assay. In brief, fluorochrome-labeled 
Annexin V reagent is used for detection of membrane phosphatidylserine (PS), which translocates to the 
cellular surface from the inner side of plasma membrane in the event of early apoptosis. Simultaneously, 
propidium iodide (PI) is used for detection of later stages of apoptosis or necrosis, which are 
characterized by loss of membrane integrity and accumulation of PI inside the cells. A2780 cells were 
treated with 2IC50 and 6IC50 concentrations of HL2 and 2 (IC50 values were obtained from MTT 
experiment in A2780 cells with the exposure time of 72 h). Results are illustrated in Figure 9. Upon 
incubation of A2780 cells with increasing concentrations of HL2 and 2, the dose-dependent increase of 
apoptotic cells was observed. 
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Figure 9. Bar graphs showing the percentage of cell death due to apoptosis (left) and necrosis (right) in A2780 cells treated 
with increasing concentrations of HL2, 2 (2IC50 and 6IC50) and CuCl2 and detected by Annexin V/PI apoptosis assay. 
Statistical analysis was performed by two-tailed T-test using GraphPad Prism software (GraphPad Software Inc., CA) with 
p < 0.05 considered as significant (* p < 0.05, ** p < 0.01).
At low concentrations both the proligand and Cu(II) complex induced a 2- to 3-fold increase of apoptotic 
cells in comparison with untreated cells (7.8  1.8 %, 17.2  3.9 % and 22.5  5.3 % for untreated cells, 
HL2 (2IC50) and 2 (2IC50), respectively). At high concentrations a further increase of apoptotic cells was 
observed (28.1  4.0% and 24.4  7.8.% for HL2 (6IC50) and 2 (6IC50)). No significant differences 
between the apoptosis-inducing properties of the proligand HL2 and 2 were noticed. When CuCl2 was 
incubated with the cells at the concentration, corresponding to Cu content in 2 at 2IC50, no induction of 
apoptosis was detected, which can be explained by poor cellular accumulation of CuCl2. The proportion 
of necrotic cells was negligible and no significant deviation from untreated cells was detected; therefore, 
the induction of necrosis by HL2 and 2 was ruled out. Subsequently, the effects of HL2 and 2 on apoptotic 
signaling in cells were investigated by Western Blotting. A2780 cells were treated with increasing 
concentrations of the drug for 24 h, and the cleavage of poly (ADP-ribose) polymerase-1 (PARP) was 
investigated (Figure 8). Cleavage of poly (ADP-ribose) polymerase-1 (PARP) through suicidal proteases 
such as caspases has been widely accepted as an indicator of apoptosis.43 As can be seen in Figure 8, 
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both HL2 and 2 revealed a dose-dependent PARP cleavage, indicating apoptosis induction in agreement 
with the results of Annexin V/PI assay. Additionally, expression of X-linked inhibitor of apoptosis 
(XIAP) was markedly reduced in a dose-dependent manner upon treatment with increasing 
concentrations of 2. 
Discussion
The diverse biological and chemical properties of Triapine and other TSCs, as well as their transition 
metal complexes, have been extensively studied for decades.44,45,46,47,48,41,49,50,51  Their antiproliferative 
and antibacterial activity varies greatly, from low nanomolar to high micromolar range, depending on 
the substituents at the TSC backbone.16,20,52 Even though clinical trials demonstrated some benefits of 
patient treatment with Triapine, its low aqueous solubility and high toxicity prevent it from further 
clinical progress. In a continuous effort to improve the bioavailability and therapeutic profile of TSCs 
and Cu(II)-TSC complexes, novel thiosemicarbazone hybrids with bioactive L-proline, homoproline, 
piperazine or iminodiacetate moieties, using the molecular hybridization approach, have been designed 
and synthesized.16,17,18,19,20 However, the improvement of the aqueous solubility was often accompanied 
by a significant decrease in cytotoxicity. In this study, the attachment of N-substituted morpholine 
moiety at the TSC backbone resulted in a simultaneous improvement of aqueous solubility and 
cytotoxicity (up to 50 times in comparison with Triapine). To ensure the selectivity of novel TSCs 
towards cancer cells over healthy cells, their cytotoxicity against A2780 cancer cells and noncancerous 
HEK293 cells was compared. It was shown that new compounds were 2‒5 fold more toxic towards 
cancer cells than healthy cells (Tables 1 and 2), whereas Triapine was more toxic towards noncancerous 
cells, which is in agreement with its known high toxicity. The coordination of TSCs to Cu(II) resulted 
in Cu(II)-TSC complexes with similar or improved antiproliferative activity. In general, when TSCs are 
coordinated to Cu(II), an increase in cytotoxicity is observed;17,18,53 however, Cu(II)-Triapine complex 
was shown to be significantly less cytotoxic than Triapine itself.27 The activity of the Cu(II) complexes 
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1‒6 was in a good correlation with their lipophilicity, cellular accumulation, as well as their 
electrochemical redox potentials (Tables S6 and 2). Interestingly, metal-free TSCs exhibited only low 
antibacterial properties against S. aureus, whereas Cu(II)-TSC complexes revealed significant 
antibacterial activity similar to that of the commonly used antibiotic ciprofloxacin (Table 4). These 
results indicate that coordination of TSCs to Cu(II) improved their therapeutic potential. It should be 
noted that the replacement of N,N,S- with N,N,N-chelating moiety in 6 resulted in a drop of cytotoxicity 
and antibacterial activity, which is in agreement with the previously reported data.20 
The antiproliferative activity of Triapine and other TSC proligands is often related to their Fe-chelating 
properties.54 To sustain their high proliferation rate, cancer cells rely on increased uptake of Fe from Fe-
transporting proteins; therefore, Fe chelation is a valuable therapeutic strategy for cancer treatment. 
Based on UV–vis and ESI-MS experiments, it was demonstrated that irrespective of metal-to-ligand 
ratio, proligands HL2 and HL5 readily reacted with Fe(III) to form [FeIII(L2)2]+ and [FeIII(L5)2]+ species, 
which could be reduced to Fe(II) bis-ligand complexes by the reducing agent DTT. These results indicate 
that morpholine-TSC hybrids, investigated in this study, may act as Fe chelators. Additionally, 
spectroelectrochemical experiments revealed that under reducing conditions, the Cu(II)-TSC complexes 
could undergo reversible reduction to Cu(I) species, with simultaneous release of proligands, suggesting 
that these complexes may act as Fe chelators, also in cancer cells. In addition, the presence of the Cu(II) 
ion in the cells may lead to the production of ROS in vivo, due to Cu(II)/Cu(I) redox cycling.55 
It is well known that one of the mechanisms contributing to the cytotoxic effects of Fe chelators is 
inhibition of the RNR enzyme, which is highly expressed in cancer cells, and essential for their DNA 
synthesis. The mechanism of RNR inhibition by Triapine has been extensively studied by several 
research groups.41,46,47,51,56 It has been proposed that Triapine interferes with the assembly of the 
differic-tyrosyl radical cofactor in R2, necessary for the catalytic activity of RNR.46,56 Moreover, it has 
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been shown that the presence of Fe is required for effective R2 inhibition,44,45 and that it is actually the 
Fe(II)-Triapine species that is responsible for the R2-specific RNR inhibitory effect of 
Triapine.41,46,47,51,58 The Fe(II)-Triapine complex may be formed by chelation of Fe from the differic 
cofactor in R2 in vitro,44,41 and/or from intracellular iron pools in vivo.46,56 The potent inhibition of 
human,47 and mouse41 R2 RNR in vitro by catalytic amounts of Fe(II)-Triapine has been proposed to 
involve ROS. Namely, ROS had been spin-trapped, and detected by EPR spectroscopy, in the aerobic 
reaction between human R2 RNR and Fe(II)-Triapine, which had implicated that O2 is important in 
tyrosyl radical destruction, and that ROS may ultimately be responsible for the pharmacologic effects of 
Triapine in vivo.47 In another study of time-dependent tyrosyl radical reduction in mouse R2 by Triapine, 
and its Zn, Ga, Cu, and Fe complexes, the requirement of O2 in R2 inhibition was also suggested.41 This 
was based on the observation that substoichiometric amounts of Fe(III)-Triapine relative to R2 (protein-
to-complex mole ratio, 5:1) reduced only 20% tyrosyl radical in anaerobic conditions, compared to 
100% in aerobic conditions. However, more recently, in a different experimental setup, namely in the 
presence of a 10-fold excess of Fe(II)-Triapine over R2 protein, the role of ROS (and O2) in human R2 
inhibition was excluded.51 This study showed that the principle mechanism of human R2 RNR inhibition 
by Triapine, based on kinetic measurements of tyrosyl radical, and 55Fe loss, is direct radical quenching, 
in an iron-loaded protein. Furthermore, it implied that Fe(II)-Triapine can rapidly reduce the tyrosyl 
radical, while leaving the protein in the met-state.
In order to investigate if R2 RNR could be the potential biomolecular target for the novel morpholine-
TSC hybrids, and their Cu(II) complexes, molecular docking studies, and R2 RNR tyrosyl radical 
reduction kinetic experiments, were performed. It has been suggested that the efficiency of R2 inhibition 
is likely to depend on the access of the inhibitors to the differic center of R2;41,47 therefore, we estimated 
the likelihood of the binding of TSC proligands HL1‒HL6 and their corresponding Cu(II) complexes 
1‒6 to the surface of the R2 protein. It was demonstrated that new TSCs, and their Cu(II) complexes 
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were deeply embedded into the pocket of the R2 protein and exhibited hydrogen bonding patterns similar 
to Triapine (Figure 7). Based on the results of the molecular docking studies suggesting plausible binding 
to the mouse R2 protein, the time-dependent tyrosyl radical reduction in the mouse R2 protein upon 
incubation with the most cytotoxic complexes, 2 and 5, and the corresponding proligands HL2 and HL5, 
at a 1:1 protein-to-compound ratio, was measured by EPR spectroscopy. Only in the presence of DTT 
(which can reduce Fe(III) to Fe(II) in the R2 differic cofactor),40 HL2 and HL5 caused 50% tyrosyl 
radical reduction (Figure S15a). These results show that R2 inactivation by HL2 and HL5 is not as 
efficient as with Triapine, which causes 100% tyrosyl radical loss in mouse R2 after 5 min (in the same 
experimental conditions).41 The most plausible explanation for this observation is that different 
mechanisms are likely to be involved in R2 inhibition by HL2, HL5 and Triapine. The R2 inhibitory 
activity of the corresponding Cu(II) complexes 2 and 5 was found to be similar to that of the proligands 
(Figure S15a). This is likely due to the fact that in the presence of DTT, the reduction of Cu(II) to Cu(I) 
leads to the release of the proligands, which is in agreement with the results of spectroelectrochemical 
experiments (vide supra). Since the UV–vis, and ESI-MS experiments showed that HL2 and HL5 act as 
tridentate ligands, and form stable Fe(II)L2 complexes (Figure S15), it is possible to propose that the 
mechanism of R2 inhibition by the TSC proligands involves Fe chelation from the differic cofactor. 
Based on the extent of tyrosyl radical reduction, it is tempting to speculate that the subsequently formed 
Fe(II) complexes are not potent inhibitors like the Fe(II)-Triapine complex. However, as this was not 
the aim of this paper, it is reasonable to refrain from any conclusions prior to the detailed mechanistic 
studies of mouse, human, and p53 R2 RNR inhibition by the morpholine-TSC hybrids. Moreover, a 
separate study should be dedicated only to the comparison of the inhibitory potentials of selected TSCs, 
and their Fe(II) complexes, in order to comprehensively understand the structure-activity relationship, 
which in turn may explain the mechanism of R2 RNR inhibition. Finally, even though R2 inhibition can 
be partially attributed to the marked anticancer activity of 2 and 5, other biomolecular targets are likely 
to be involved (Figure 10). 
Page 29 of 60
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
30
Figure 10. Proposed molecular mechanism of complex 2.
Fe homeostasis is an intrinsically complex process; hence, Fe sequestration results in the alteration of 
various biomolecular pathways. Besides RNR, Fe depletion affects multiple molecular targets including 
those regulating the cell cycle.57 It has been reported that the expression of cyclin D1, which ensures the 
progression through the G1/S phase, was strongly dependent on the cellular Fe status.58 It is believed that 
in Fe-depleted conditions, down-regulation of cyclin D1 prevents cells from entering the S phase, where 
Fe is needed for the activity of the RNR enzyme and DNA synthesis.59 Fe chelation by TSCs often 
results in the down-regulation of cyclin D1 and subsequent cell cycle arrest at the G1/S phase.60,61 As 
expected, complex 2 was shown to induce strong dose-dependent down-regulation of cyclin D1, whereas 
the protein expression of cyclin B1, which is responsible for G2/M progression, remained unchanged. In 
order to further investigate the potential biomolecular targets of Fe-chelating compounds of interest, we 
studied the phosphorylation of ERK protein, which belongs to the MAPK family. The MAP kinases 
occupy the central position in cell growth and apoptosis and each MAP kinase member plays a different 
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role in cellular responses.62 It was reported that some Fe chelators induced cancer cell death associated 
with the activation of p38 MAPK and ERK.63 Moreover, the MAPK-mediated cell death was 
characterized by the decreased expression of cyclin D1.64 Complex 2, as well as the corresponding 
proligand HL2 caused dose-dependent phosphorylation ERK in line with its activation, suggesting that 
MAPK pathway might be a potential mediator of the cell death, induced by this complex.
 
Recently, it was discovered that chelation and depletion of intracellular Fe leads to the activation of 
certain ER stress-response proteins.65,66 Previously, several TSCs and their Cu(II) complexes were 
reported to induce ER stress, characterized by UPR activation,67,68 ER expansion and release of 
intracellular calcium.69 Since under reducing conditions, the novel TSCs and their Cu(II) complexes 
demonstrated formation of Fe(II)-TSC complexes, it may be suggested that they could possibly induce 
sequestration of cellular Fe resulting in the ER stress. It occurs due to the accumulation of misfolded 
and/or unfolded proteins in ER, resulting in the disruption of cellular homeostasis. In order to overcome 
stress, cells activate a rescue program known as UPR, which operates via several signaling pathways, 
namely ATF6, PERK and IRE1α. However, in case of severe ER stress, the pro-survival program is 
switched off and pro-apoptotic signaling takes place, characterized by the enhanced expression of CHOP 
protein. Complex 2 was shown to induce dose-dependent increase in the expression of IRE1α and CHOP 
proteins, indicating the induction of UPR signaling as a result of ER stress. Cell treatment with 2 resulted 
in a concentration-dependent decrease of BiP/GRP78 protein marker. The ER chaperon BiP/GRP78 
plays a central role in the survival machinery and its overexpression is associated with tumor progression 
and metastases.70 The inhibition of BiP/GRP78 indicates severe ER stress, resulting in the suppression 
of pro-survival chaperones. The antibacterial properties of novel Cu(II)-TSC complexes can be also 
related to ER stress induction, since it was recently demonstrated in vitro and in vivo experiments that 
chemical modulation of ER stress might result in the overload of its machinery that can be effective in 
elimination of bacterial infection.71 Additionally, it was reported that efficient killing of methicillin-
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resistant S. aureus was dependent on the induction of IRE1α UPR pathway and required sustained 
generation of ROS.72 Based on the observations that 2, but not proligand HL2 induced antioxidant 
defence in cancer cells characterized by NRF2 induction, it may be speculated that the ability of 2, but 
not proligand HL2, to induce oxidative and ER stress, may be related to the beneficial antibacterial 
activity of Cu(II)-TSC complexes over metal-free TSCs. However, it is not clear yet why new complexes 
1‒6 did not inhibit the growth of P. aeruginosa and their mechanism of action should be investigated in 
more detail. 
In order to cope with the severe perturbations imposed by drug treatment, cancer cells develop adaptive 
responses to provide them with survival advantage. However, novel TSCs and their Cu(II) complexes 
significantly disturbed cellular life-death balance towards cell death resulting in the induction of 
apoptosis. Both proligand HL2, and complex 2 were demonstrated to induce apoptosis characterized by 
PARP cleavage, decreased expression of XIAP and increased PS translocation. It should be noted that 
XIAP is a determining factor of cisplatin chemoresistance in ovarian cancer cells as it effectively 
suppresses apoptosis via caspase-3 and caspase-7 inhibition.73 Therefore, the ability of 2 to decrease 
XIAP expression is highly important and to the best of our knowledge has not been previously reported 
for TSCs and metal thiosemicarbazonates, with the exception of Triapine.74 Some TSCs and their 
respective Cu(II) complexes have been reported to simultaneously induce various types of cell death 
including apoptosis,75,76 autophagy76,77 and methuosis, which is a very special form of non-apoptotic cell 
death involving massive cytoplasmic vacuolization.78 Therefore, induction of other forms of cell death 
by new TSCs and their Cu(II) complexes presented in this study cannot be excluded. The results show 
that the attachment of the morpholine moiety at the TSC backbone and the subsequent coordination to 
Cu(II), resulted in new drug candidates, likely with better therapeutic profile than Triapine and a 
promising potential for further clinical development.  
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Conclusions
One of the reasons hindering the clinical development of Cu(II) thiosemicarbazone complexes is their 
low aqueous solubility. The decoration of the TSC backbone with functional groups that increase the 
aqueous solubility and bioavailability often results in a significant decrease of the compound activity. In 
this work, attachment of a morpholine moiety to 2-formylpyridine (iso)thiosemicarbazone in position 5 
of 2-formylpyridine moiety yielded new water-soluble TSC-morpholine hybrids and their Cu(II) 
complexes, which demonstrated high antiproliferative activity against cisplatin-sensitive and cisplatin-
resistant ovarian carcinoma cells, in a nanomolar to submicromolar concentration range. Sufficient 
aqueous solubility of  the new compounds enabled the study of their solution behavior and 
electrochemical properties under conditions similar to the intracellular environment. Solution speciation 
studies of 1 revealed that the dissociation of the complex does not occur at the physiological pH, even 
at micromolar concentrations, indicating its high stability in aqueous media. However, under reducing 
conditions associated with the cancer cell environment, the reversible reduction of Cu(II) with 
subsequent release of the proligand within the biologically accessible electrochemical window is 
plausible. Since the R2 RNR protein is believed to be one of the biomolecular targets of TSCs, and the 
fact that the proligands form 2:1 complexes with Fe(II), the chelation of Fe(II) from R2 was expected. 
The Cu(II)-TSCs and their corresponding proligands showed only moderate Tyrosyl radical reduction 
in mouse R2. Therefore, the marked anticancer activity of the compounds investigated in this work was 
not solely related to their RNR inhibitory potential, but also to the induction of apoptosis as a result of 
ER stress, MAPK activation and cell cycle perturbations. Studies of the mechanisms controlling cellular 
accumulation of the lead drug 2 have shown that it accumulates in cancer cells as a result of passive 
and/or facilitated diffusion. Finally, it was discovered that coordination of TSC ligands to Cu(II) resulted 
in a significant enhancement of their antibacterial properties against S. aureus. The combination of 
excellent antiproliferative and antibacterial activity, as well as water-solubility, is a sound basis for 
further development of this class of Cu(II) thiosemicarbazonates as dual pharmaceutical agents.  
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Experimental
1. Chemicals. 2,5-Pyridinecarboxylic acid was purchased from Alfa Aesar. Ethylenediaminetetraacetic 
acid (EDTA), KOH and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) were purchased 
from Sigma-Aldrich in puriss quality. KCl, CuCl2, hydrochloric acid and n-octanol are products of Molar 
Chemicals. CuCl2 stock solution was prepared from anhydrous CuCl2 and water and its exact 
concentration was determined by complexometry through the EDTA complex. All solvents were of 
analytical grade and used without further purification. Milli-Q water was used for sample preparation. 
The synthesis of the 5-methylmorpholine-pyridine-2-carboxaldehyde H (Scheme 1) is described in detail 
in Supporting Information. Chemical grade cisplatin (1 mg/mL) was purchased from Hospira Pty Ltd 
(Melbourne, Australia). IGEPAL CA-630, DL-dithiothreitol (DTT), tetramethylethylenediamine 
(TEMED), sodium deoxycholate, non-fat dried milk bovine, TWEEN® 20, ponceau S, propidium iodide 
(PI) were purchased from Sigma-Aldrich (St Louis, MO, USA). Thiazolyl Blue tetrazolium bromide 
(MTT) was purchased from Alfa Aesar. Tris was purchased from Vivantis Technologies. Glycine, 
HycloneTM Trypsin Protease 2.5% (10) solution, RPMI 1640, DMEM medium, Fetal bovine serum 
(FBS), Bovine Serum Albumin (BSA), Hank’s Balanced Salt Solution (HBSS) and PierceTM Protease 
and Phosphatase Inhibitor Mini Tablets were purchased from Thermo Fisher Scientific. HycloneTM 
Dulbecco's Phosphate-Buffered Saline (10), were purchased from GE Healthcare Life Sciences. Biorad 
protein assay dye reagent concentrate, 30% Acrylamide/Bis solution, 5 Laemmli Sample Buffer, 
Nitrocellulose Membrane (0.2 m) were purchased from Bio-rad Laboratories. LuminataTM Classico 
and Crescendo Western HRP substrate were purchased from Merck Millipore Corporation. Milli-Q-
grade purified water was obtained from a Milli-Q UV purification system (Sartorius Stedim Biotech 
S.A., Aubagne Cedex, France). All antibodies were obtained from Cell Signaling Technologies 
(Beverly, MA, USA). Nitric acid (65% to 71%, TraceSELECT Ultra) for ICP-MS analysis and 
nBu4NPF6 for cyclic voltammetry experiments were obtained from Fluka (Sigma Aldrich) and used 
without further purification. Cu and In standards for ICP-MS measurements were obtained from CPI 
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international (Amsterdam, The Netherlands). Cycloheximide, oligomycin, annexin V-FITC apoptosis 
detection reagent (500X) were purchased from Abcam (Cambridge, UK). 
2. Synthesis of proligands.
The yields, m.p. and analytical data for HL1‒HL6 and 1‒6 are presented in Tables S9 and S10. The 
experimental CHNS contents were within ±0.4 with those calculated, providing evidence for ≥95% 
purity. 
5-(morpholinomethyl)pyridine-2-carboxaldehyde thiosemicarbazone (HL1). 5-morpholinomethyl-
pyridine-2-carboxaldehyde (0.29 g, 1.41 mmol), thiosemicarbazide (0.13 g, 1.41 mmol) and EtOH (5 
mL) were mixed in a 25 mL Shlenk tube. The reaction mixture was stirred at 78 °C overnight. The next 
day the reaction mixture was cooled to room temperature and stored at 4 °C for 4 h. The white crystalline 
precipitate was filtered off, washed with cold EtOH and dried in vacuo. Yield: 0.34 g. 1H NMR 500 
MHz (DMSO-d6, δ, ppm): 1H NMR (500 MHz, DMSO) δ 11.62 (s, 1H, NH16), 8.48 (d, J = 1.3 Hz, 1H, 
H6), 8.34 (s, 1H, NH19), 8.24 (d, J = 8.1 Hz, 1H, H3), 8.15 (s, 1H, NH19), 8.09 (s, 1H, H14), 7.74 (dd, J = 
8.2, 1.7 Hz, 1H, H4), 3.59 – 3.54 (m, 4H, H10, H12), 3.51 (s, 2H, H7), 2.36 (s, 4H, H9, H13). 13C NMR 
(126 MHz, DMSO) δ 178.74 (Cq, C17), 152.73 (Cq, C2), 150.12 (CH, C6), 142.85 (CH, C14), 137.51 (CH, 
C4), 134.23 (Cq, C5), 120.23 (CH, C3), 66.57 (2CH2, C10, C12), 59.74 (CH2, C7), 53.49 (2CH2, C9, C13). 
IR (ATR, selected bands, ῦmax): 1612, 1527, 1468, 1400, 1339, 1274, 1102, 1004, 938, 859, 626 cm‒1. 
5-(morpholinomethyl)pyridine-2-carboxaldehyde 4,4-dimethyl-3-thiosemicarbazone (HL2). 5-
(morpholinomethyl)pyridine-2-carboxaldehyde (0.29 g, 1.41 mmol) and 4,4-dimethyl-3-
thiosemicarbazide (0.17 g, 1.41 mmol) were dissolved in EtOH (5 mL) and stirred in a Shlenk tube at 
78 °C for 2 h until the solution became clear. The reaction mixture was left to stand at 4 °C for 6 h. The 
yellow crystalline precipitate was filtered off, washed with cold EtOH and dried in vacuo. Yield: 0.25 
g. 1H NMR (500 MHz, DMSO) δ 15.08 (s, 1H, NH16), 8.71 (s, 1H, H3), 8.49 (s, 1H, H6), 8.23 (d, 1H, 
H14), 7.76 (dd, J = 13.9, 8.1 Hz 1H, H4), 3.59 (s, 4H, H10, H12), 3.52 (s, 2H, H7), 3.38 (s, 4H, H20, H21), 
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2.37 (s, 4H, H9, H13).13C NMR (126 MHz, DMSO) δ 180.02 (Cq, C17), 153.06 (Cq, C2), 150.27 (CH, C6), 
148.84 (CH, C3), 144.29 (CH, C14), 137.75 (CH, C4), 134.06 (Cq, C5), 66.61 (2CH2, C10, C12), 59.77 
(CH2, C7), 53.53 (2CH2, C9, C13), 42.72 (2CH3, C20, C21). IR (ATR, selected bands, ῦmax): 1497, 1443, 
1362, 1303, 1209, 1158, 1108, 1064, 1003, 901, 862, 716, 627 cm‒1. 
5-(morpholinomethyl)pyridine-2-carboxaldehyde N-pyrrolidinylthiosemicarbazone (HL3). 5-
(morpholinomethyl)pyridine-2-carboxaldehyde (0.29 g, 1.41 mmol) and N-pyrrolidine-3-
thiosemicarbazide (0.20 g, 1.41 mmol) were dissolved in EtOH (5 mL) and stirred in a Shlenk tube at 
78 °C for 2 h until the solution became clear. The mixture was left to stand at 4 °C for 12 h. The yellow 
crystalline precipitate was filtered off, washed with cold EtOH and dried in vacuo. Yield: 0.36 g. 1H 
NMR (500 MHz, DMSO) δ 11.23 (s, 1H, NH16), 8.49 (d, J = 1.4 Hz, 1H, H3), 8.20 (s, 1H, H6), 8.01 (dd, 
J = 8.0, 2.1 Hz, 4H, H21, H22), 7.84 (s, 1H, H14), 7.77 (d, J = 1.9 Hz, 1H, H4), 3.76 (s, 4H, H20, H23), 3.59 
(dd, J = 8.1, 5.3 Hz, 4H, H9, H13), 3.52 (s, 2H, H7), 2.42 – 2.32 (m, 4H, H10, H12). 13C NMR (126 MHz, 
DMSO) δ 177.02 (C, C17), 153.11 (C, C2), 150.17 (CH, C6), 149.02 (CH, C3), 143.48 (CH, C14), 139.44, 
(2CH2, C21, C22), 138.08 (CH, C16), 134.05 (C, C5), 119.43 (CH, C3), 66.62 (2CH2, C9, C13), 59.91 (CH2, 
C7), 53.53 (2CH2, C20, C23), 40.00 (2CH2, C10, C12, overlapped with residual DMSO signal). IR (ATR, 
selected bands, ῦmax): 1585, 1529, 1419, 1347, 1287, 1108, 1001, 855, 796, 741 cm‒1. 
5-(morpholinomethyl)pyridine-2-carboxaldehyde N-morpholinylthiosemicarbazone (HL4). 5-
(morpholinomethyl)pyridine-2-carboxaldehyde (0.29 g, 1.41 mmol) and N-morpholinyl-3-
thiosemicarbazide (0.23 g, 1.41 mmol) were dissolved in EtOH (5 mL) and stirred in a Shlenk tube at 
78 °C for 2.5 h until the solution became clear. Light-yellow crystals formed within 3 weeks at 4 °C 
after concentration of the reaction mixture. These were filtered off, washed with cold EtOH and dried in 
vacuo. Yield: 0.12 g.  1H NMR (500 MHz, DMSO) δ 11.43 (s, 1H, NH16), 8.50 (d, J = 1.3 Hz, 1H, H6), 
8.18 (s, 1H, H14), 7.83 (d, J = 8.1 Hz, 1H, H4), 7.78 (dd, J = 8.2, 1.9 Hz, 1H, H3), 3.98 – 3.91 (m, 4H, 
H20, H24), 3.72 – 3.66 (m, 4H, H21, H23), 3.60 – 3.55 (m, 4H, H9, H13), 3.52 (s, 2H, H7), 2.36 (br. s, 4H, 
H10, H12). 13C NMR (126 MHz, DMSO) δ 181.27 (Cq, C17), 152.75 (Cq, C4), 150.33 (CH, C6), 144.44 
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(CH, C14), 137.83 (CH, C3), 134.27 (CH, C2), 119.60 (Cq, C4), 66.60 (2CH2, C21, C23), 66.48 (CH2, C7), 
59.73 (2CH2, C9, C13).  
5-(morpholinomethyl)pyridine-2-carboxaldehyde 4-phenylthiosemicarbazone (HL5). 5-
(morpholinomethyl)pyridine-2-carboxaldehyde (0.29 g, 1.41 mmol) and 4-phenyl-3-thiosemicarbazide 
(0.24 g, 1.41 mmol) were dissolved in EtOH (5 mL) and stirred in a Shlenk tube at 78 °C for 3 h until 
the solution became clear. Then the reaction mixture was allowed to stand at 4 °C for 12 h. The yellow 
crystalline precipitate was filtered off, washed with cold EtOH and dried in vacuo. Yield: 0.32 g. 1H 
NMR (500 MHz, DMSO) δ 12.02 (s, 1H, NH16), 10.24 (s, 1H, NH18), 8.52 (s, 1H, H6), 8.41 (d, J = 8.1 
Hz, 1H, H3), 8.21 (s, 1H, H14), 7.78 (d, J = 10.1 Hz, 1H, H4), 7.56 (d, J = 8.6 Hz, 2H, H21, H25), 7.40 (t, 
J = 7.9 Hz, 2H, H22, H24), 7.24 (t, J = 7.4 Hz, 1H, H23), 3.59 (s, 4H, H10, H12), 3.54 (s, 2H, H7), 2.38 (s, 
4H, H9, H13).13C NMR (126 MHz, DMSO) δ 176.84 (Cq, C17), 152.62 (Cq, C2), 150.25 (CH, C6), 143.45 
(Cq, C14), 139.44 (Cq, C20), 137.51 (CH, C4), 134.46 (Cq, C5), 128.59 (2CH, C22, C24), 126.56 (2CH, C21, 
C25), 120.68 (CH, C3), 66.62 (2CH2, C10, C12), 53.54 (2CH2, C9, C13), 40.00 (CH2, C7). IR (ATR, selected 
bands, ῦmax): 1592, 1505, 1466, 1338, 1291, 1188, 1105, 1060, 1000, 944, 909, 863, 791, 751, 689, 634 
cm‒1. 
5-(morpholinomethyl)pyridine-2-carboxaldehyde S-methylisothiosemicarbazone (HL6). To a 
solution of 5-(morpholinomethyl)pyridine-2-carboxaldehyde (0.29 g, 1.41 mmol) in EtOH (6 mL) was 
added a solution of S-methylisothiosemicarbazide hydroiodide (0.33 g, 1.41 mmol) in water (2 mL). 
Then the raction mixture was heated to 60 °C and a solution of NaHCO3 (0.118 g, 1.41 mmol) in water 
(4 mL) was added dropwise. When bubbles of CO2 disappeared, the mixture was allowed to cool to 
room temperature. The solvent was removed under reduced pressure and the residue dissolved in water. 
The product was extracted with chloroform. After removal of the solvent the residue was dissolved in a 
small amount of EtOH and allowed to stand at ‒20 °C overnight. Light-brown crystalline product was 
obtained the next day. Yield: 0.14 g. 1H NMR (500 MHz, DMSO) δ 8.49 (d, J = 1.4 Hz, 1H, H4), 8.21 
(d, J = 8.1 Hz, 1H, H14), 8.17 (s, 1H, H6), 7.84 (d, J = 8.1 Hz, 1H, H3), 7.16 (s, 2H, H18), 3.60-3.55 (m, 
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8H, H9, H13), 3.51 (s, 2H, H7), 2.40 (br. s, 3H, H20), 2.36 (d, J = 6.0 Hz, 8H, H10, H12). 13C NMR (126 
MHz, DMSO) δ 164.19 (C, C17), 154.02 (C, C5), 151.84 (CH, C6), 150.12 (CH, C4), 137.35 (CH, C3), 
133.89, (C, C2), 120.68 (CH, C14), 66.61 (2CH2, C9, C13), 59.84 (CH2, C7), 53.53 (2CH2, C10, C12), 12.52 
(CH3, C20). IR (ATR, selected bands, ῦmax): 1600, 1497, 1472, 1335, 1290, 1111, 1069, 1015, 931, 870, 
790, 752, 714, 626 cm-1. 
3. Synthesis of Cu(II) complexes.
[Cu(L1)Cl] (1). To HL1 (100 mg, 0.36 mmol) in MeOH (20 mL) was added triethylamine (50 µl, 0.36 
mmol) and then CuCl2·2H2O (60 mg, 0.36 mmol) in MeOH (5 mL) at 60 °C. The solution was stirred 
for 5 min and left to stand at room temperature overnight. The precipitate formed was filtered off, washed 
with cold EtOH and dried in air. Yield: 123 mg. IR (ATR, selected bands, ῦmax): 1631, ´1426, 1310, 
1158, 1107, 1060, 907, 722, 688 cm‒1. 
[Cu(L2)Cl] (2). To HL2 (100 mg, 0.32 mmol) in MeOH (20 mL) was added triethylamine (44.5 µL, 
0.32 mmol) and then CuCl2·2H2O (54 mg, 0.32 mmol) in MeOH (5 mL) at 60 °C. The solution was 
stirred for 5 min and left to stand at room temperature overnight. The precipitate formed was filtered off, 
washed with cold EtOH and dried in air. Yield: 104 mg. IR (ATR, selected bands, ῦmax): 1505, 1372, 
1310, 1252, 1111, 1000, 913, 872, 749, 626 cm‒1. 
[Cu(L3)Cl] (3). To HL3 (100 mg, 0.3 mmol) in MeOH (20 mL) was added triethylamine (42 µl, 0.28 
mmol) and then CuCl2·2H2O (50 mg, 0.3 mmol) in MeOH (5 mL) at 60 °C. The solution was stirred for 
5 min and left to stand at room temperature overnight. The precipitate formed was filtered off, washed 
with cold EtOH and dried in air. Yield: 74 mg. IR (ATR, selected bands, ῦmax): 1444, 1375, 1281, 1242, 
1111, 1004, 913, 885, 623 cm‒1. 
[Cu(L4)Cl] (4). To HL4 (50 mg, 0.28 mmol) in MeOH (20 mL) was added triethylamine (20 µl, 0.28 
mmol) and then CuCl2·2H2O (25 mg, 0.28 mmol) in MeOH (5 mL) at 60 °C. The solution was stirred 
for 5 min and left to stand at room temperature overnight. The precipitate formed was filtered off, washed 
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with cold EtOH and dried in air. Yield: 22 mg. IR (ATR, selected bands, ῦmax): 1465, 1429, 1381, 1313, 
1265, 1229, 1109, 1028, 932, 888, 860 cm‒1. 
[Cu(L5)Cl] (5). To HL5 (100 mg, 0.28 mmol) in MeOH (20 mL) was added triethylamine (39 µl, 0.28 
mmol) and then CuCl2·2H2O (47 mg, 0. 82 mmol) in MeOH (5 mL) on heating. The solution was stirred 
for 5 min and left to stand at room temperature overnight. The precipitate formed was filtered off, washed 
with cold EtOH and dried in air. Yield: 67 mg. IR (ATR, selected bands, ῦmax): 1600, 1550, 1493, 1417, 
1182, 1111, 1000, 899, 863, 799, 752, 691 cm‒1. 
[Cu(L6)Cl] (6). To HL6 (100 mg, 0.34 mmol) in MeOH (20 mL) was added triethylamine (47 µl, 0.34 
mmol). Then the reaction was heated to 40 °C and CuCl2·2H2O (58 mg, 0.34 mmol) in MeOH (5 mL) 
was added. The solution was stirred for 5 min at 50 °C and left to stand at ‒20 °C overnight. The 
precipitate formed was filtered off, washed with ethanol, ether and dried in air. Yield: 75 mg. IR (ATR, 
selected bands, ῦmax): 1599, 1491, 1431, 1320, 1115, 1035, 1004, 973, 911, 796, 724 cm‒1. 
4. Solution equilibrium studies in aqueous phase
pH-potentiometric measurements. These measurements were performed as described previously.16 
The initial volume of the samples was 10.0 mL. The ligand concentration was 1 mM and metal ion-to-
ligand ratios of 1:1 − 1:3 were used. The exact concentration of the ligand stock solutions together with 
the proton dissociation constants were determined by pH-potentiometric titrations with the use of the 
computer program HYPERQUAD.79 HYPERQUAD was also utilised to establish the stoichiometry of 
the complexes and to calculate the stability constants (log(MpLqHr)). (MpLqHr) is defined for the 
general equilibrium pM + qL + rH  MpLqHr as (MpLqHr) = [MpLqHr]/[M]p[L]q[H]r, where M 
denotes the metal ion and L the completely deprotonated ligand. The uncertainties (standard deviations, 
SD) of the equilibrium constants are shown in parentheses for the species determined in the present 
work.
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5. Instrumentation. ICP-OES determination of Cu content was performed in Chemical, Molecular and 
Analysis Centre, National University of Singapore with Optima ICP-OES (Perkin Elmer, Watham, MA, 
USA). The absorbance of thiazolyl blue tetrazolium bromide (MTT) was measured by synergy H1 
hybrid multimode microplate reader (Bio-Tek, Winoosky, VT, USA). Cu and Re contents in cells were 
determined by Agilent 7700 Series ICP-MS (Agilent Technologies, Santa Clara, CA, USA). Flow 
cytometry was performed on BD LSRFortessa Cell Analyzer (BD Biosciences, Franklin Lakes, NJ, 
USA). Western blot images were generated from G:Box (Syngene, Cambride, UK).  The UV‒vis 
spectrophotometric measurements were performed on a Hewlett Packard 8452A diode array 
spectrophotometer and a Thermo Scientific Evolution 220 spectrophotometer. CW-EPR spectra were 
recorded with a BRUKER EleXsys E500 spectrometer. In situ ultraviolet-visible-near-infrared 
(UV‒vis‒NIR) spectroelectrochemical measurements were performed on a spectrometer (Avantes, 
Model AvaSpec-2048x14-USB2.
6. UV–vis spectrophotometric, 1H NMR, EPR and lipophilicity measurements. UV‒vis spectra were 
recorded in the ranges 200‒800 nm and 450‒1050 nm, respectively. The path length was 0.5, 1 or 2 cm. 
Stability constants of the complexes and the molar absorbance spectra of the individual species were 
calculated with the computer program PSEQUAD.80 The spectrophotometric titrations were performed 
on samples containing the proligand with or without Cu(II) ions and the concentration of the proligand 
was 120 M ‒ 1.4 mM. The metal-to-proligand ratios were 1:1 and 1:2 in the pH range from 1.0 to 11.5 
at 25.0 ± 0.1 °C at an ionic strength of 0.10 M (KCl). pH values in the range 1.0–2.0, were calculated 
from the strong acid and strong base content. The conditional stability constant of [CuL] at pH 6.0 (50 
mM MES) for 1 was determined from competition titrations of the Cu(II) complex of EDTA with the 
proligand HL1. Samples contained 34 μM Cu(II) ion and 34 µM HL1, and the concentration of the 
EDTA was varied in the range of 0–83 μM. Absorbance data were recorded after 0.5 h incubation. 1H 
NMR studies for HL1 were carried out on a Bruker Avance III HD Ascend 500 Plus instrument in a 10% 
(v/v) D2O/H2O mixture at ionic strength of 0.10 M (KCl). All CW-EPR spectra were recorded with a 
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BRUKER EleXsys E500 spectrometer (microwave frequency 9.85 GHz, microwave power 10 mW, 
modulation amplitude 5 G, modulation frequency 100 kHz. The pH dependent series of isotropic EPR 
spectra were recorded in a circulating system, at room temperature. A Heidolph Pumpdrive 5101 
peristaltic pump was used for circulate the solution from the titration pot through a capillary tube into a 
Bruker flat cell placed in the cavity of the instrument. The titrations were carried out under nitrogen 
atmosphere. EPR spectra were recorded at 1.00 mM Cu(II) and 0.75 mM ligand concentration, and at 
1.00 mM CuCl2 and 1.50 mM ligand concentration, both between pH = 1 – 11.5. The ionic strength of 
0.1 M was adjusted with KCl. Before the simulation of the room temperature spectra, the measured 
spectra were corrected by subtracting the spectra of aqua solution measured in the same circulating 
system. The series of pH-dependent isotropic EPR spectra recorded in the equimolar solution were 
simulated by the „two-dimensional” method using the 2D_EPR program81  and EPR parameters were 
computed as published previously.16,25 Distribution coefficients (D7.4) values of complexes 1‒6 and 
HL1‒HL6 were determined by the traditional shake-flask method in n-octanol/buffered aqueous solution 
at pH 7.40 (20 mM HEPES, 0.10 M KCl) at 25.0 ± 0.2 °C as described previously.82
7. Crystallographic Structure Determination. X-ray diffraction quality single crystals of HL1, HL2, 
HL4‒HL6 were obtained by recrystallization in ethanol, while 1 and 3‒6 by slow diffusion of diethyl 
ether into the DMF and methanolic solution of the complexes, respectively. The measurements  were 
performed on a Bruker X8 APEX-II CCD (HL1, HL2, HL4, HL5, 1´, 3‒6), Bruker D8 Venture (1) or 
Gemini (HL6) diffractometer. Single crystals were positioned at 35, 35, 35, 35 and 55 mm from the 
detector, and 388, 1110, 946, 1108 and 2935 frames were measured, each for 40, 3, 60, 3 and 32s over 
0.5, 0.5, 0.5, 0.5 and 1.0° scan width for HL1‒HL6, respectively. For Cu(II) complexes 1, 1´, 3‒6 the 
single crystals were placed at 24, 35, 35, 33, 35 and 24 mm from the detector, and 8088, 2692, 794, 
1212, 1261 and 567 fames were measured, each for 3, 2, 60, 60, 60 and 3s over 0.6, 0.5, 0.5, 0.5, 0.4 and 
0.5° scan width, respectively. The data were processed using SAINT or CrysAlis software.83,84 Crystal 
data, data collection parameters, and structure refinement details are given in Tables S11 and S12. The 
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structures were solved by direct methods and refined by full-matrix least-squares techniques. Non-H 
atoms were refined with anisotropic displacement parameters. H atoms were inserted in calculated 
positions and refined with a riding model. The morpholine group and the N-piperidinyl unit in one of 
three crystalographically independent molecules in the asymmetric unit were found to be disordered 
over two positions with s.o.f. 0.5:0.5 and 0.6:0.4 in 3·0.25MeOH. The morpholine moiety attached to 
pyridine unit in one of the three crystallographically independent molecules of 4·0.58MeOH was found 
to be disordered over two positions with s.o.f. 0.7:0.3, while one molecule of methanol over two 
positions with s.o.f. 0.75:0.25. The positional parameters of disordered atoms were refined by using 
PART, DFIX and SADI tools implemented in SHELX. The following computer programs and hardware 
were used: structure solution, SHELXS-2014 and refinement, SHELXL-2014;85 molecular diagrams, 
ORTEP;86 computer, Intel CoreDuo. CCDC 1850567‒1850577.
8. Electrochemistry and spectroelectrochemistry. Cyclic voltammetric experiments were performed 
as described previously.53 The cyclic voltammograms were measured in the catodic region in different 
solvents (DMSO, methanol, DMSO/H2O). The analytical purity grade LiClO4 (Sigma-Aldrich) and 
distilled and deionized water were used for preparation of 1 mM aqueous solutions of the investigated 
complexes 1‒6. EPR spectra were recorded with the EMX plus. In situ ultraviolet-visible-near-infrared 
(UV‒vis‒NIR) spectroelectrochemical measurements were performed on a spectrometer (Avantes, 
Model AvaSpec-2048x14-USB2 in the spectroelectrochemical cell kit (AKSTCKIT3) with the Pt-
microstructured honeycomb working electrode, purchased from Pine Research Instrumentation. The cell 
was positioned in the CUV‒UV Cuvette Holder (Ocean Optics) connected to the diode-array 
UV‒vis‒NIR spectrometer by optical fibers. UV‒vis‒NIR spectra were processed using the AvaSoft 7.7 
software package. Halogen and deuterium lamps were used as light sources (Avantes, Model AvaLight-
DH-S-BAL). The in situ EPR spectroelectrochemical experiments were carried out under an argon 
atmosphere in the EPR flat cell equipped with a large platinum mesh working electrode. The freshly 
prepared solutions were carefully purged with argon and the electrolytic cell was polarized in the 
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galvanostatic mode directly in the cylindrical EPR cavity TM-110 (ER 4103 TM) and the EPR spectra 
were measured in situ.
9. Cell lines and culture conditions. Human ovarian carcinoma cells A2780 and A2780cisR, and 
human embryonic kidney HEK293 were obtained from ATCC. A2780 and A2780cisR cells were 
cultured in RPMI 1640 medium containing 10% fetal bovine serum (FBS). HEK293 were cultured in 
DMEM medium containing 10% FBS. All cells were grown in tissue culture 25 cm2 flasks (BD 
Biosciences, Singapore) at 37 °C in a humidified atmosphere of 95% air and 5% CO2. All drug stock 
solutions were prepared in sterile water. The amount of Cu was determined by ICP-OES. All compounds 
were soluble in water; more specifically, the solubility of 1, 2 and 5 was moderate and did not exceed 2 
mM, whereas 3 was less soluble (0.3 mM) in water.
10. Inhibition of cell viability assay. The cytotoxicity of the compounds was determined by 
colorimetric microculture assay (MTT assay, MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide) as described previously.53 
11. Cellular accumulation. Cellular accumulation of 1‒6 was determined in A2780 cells. Cells were 
seeded into Cellstar 6-well plates (Greiner Bio-one) at a density of 60  104 cells/well (2 mL per well). 
After the cells were allowed to resume exponential growth for 24 h, they were exposed to 1‒6 at 1 μM 
for 24 h at 37 C. The cells were washed twice with 1 mL of PBS and lysed with RIPA lysis buffer for 
5–10 min at 4 °C. The cell lysates were scraped from the wells and transferred to separate 1.5 mL 
microtubes. The supernatant was then collected after centrifugation (13 000 rpm, 4 °C for 15 min) and 
total protein content of each sample was quantified via Bradford’s assay. Cell lysates were transferred 
to 2 mL glass vials and then digested with ultrapure 65% HNO3 at 100 C for 24 h. The resulting solution 
was diluted to 1 mL (2‒4% v/v HNO3) with ultrapure Milli-Q water. Cu content of each sample was 
quantified by ICP-MS. In was used as an internal standard. Cu and In were measured at m/z 64 and m/z 
115, respectively. Metal standards for calibration curve (0, 0.5, 1, 2, 5, 10, 20, 40 ppb) were freshly 
prepared before each measurement. All readings were made in triplicates in He mode. For temperature-
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dependent cellular accumulation experiments, A2780 cells were seeded into 3510 mm tissue culture 
plates at a density of 60104 cells/plate. After the cells were allowed to resume exponential growth for 
24 h, they were exposed to 2 at 3 μM for 10, 30, 60 and 120 min at 37 and 4 C. The subsequent analysis 
was performed as described above. For energy-dependent experiments, A2780 cells were seeded into 
3510 mm tissue culture plates at a density of 1106 cells/plate. After the cells were allowed to resume 
exponential growth for 24 h, they were pre-incubated with oligomycin (5 μM) for 1 h or 4 h or with 
cycloheximide (100 μM) for 4 h and further co-incubated with 3 μM of 2 at 37 C. To induce total 
starvation, after the cells were allowed to resume exponential growth for 24 h, RPMI media was replaced 
with Hanks’ Balanced Salt Solution (HBSS) and cells were pre-incubated in HBSS for 1 h and further 
incubated with 3 μM of 2 for 1 h at 37 C. The subsequent analysis was performed as described above.
12. Western blot analysis. A2780 cells were seeded into Cellstar 6-well plates (Greiner Bio-One) at a 
density of 60  104 cells/well (2 mL per well). After the cells were allowed to resume exponential growth 
for 24 h, they were exposed to HL2 and 2 at different concentrations for 24 h. The experiment was 
performed essentially as described previously.53 The membranes were blocked in 5% BSA (w/v) in 
TBST wash buffer for 1 h and subsequently incubated with the appropriate primary antibodies in 5% 
BSA (w/v) in TBST wash buffer (actin antibody) at 4 °C overnight. The membranes were washed with 
a wash buffer 3 times for 5 min. After incubation with horseradish peroxidase-conjugated secondary 
antibodies (room temperature, 1.5 h), the membranes were washed with a wash buffer 4 times for 5 min. 
Immune complexes were detected with Luminata HRP substrates and analyzed using enhanced 
chemiluminescence imaging. Actin was used as a loading control. The following antibodies were used: 
NRF2 (sc13032) from Santa Cruz Biotechnologies, ECL Antirabbit IgG (NA934 V) and ECL 
Antimouse IgG (NA931) from GE Healthcare Life Sciences, cleaved PARP (Asp214) (D64E10), PARP, 
CHOP (D46F1), BiP (C50B12), IRE1α (14C10), -actin (13E5), phospho-p44/p42 MAPK (Erk1/2) 
(Thr202/Tyr204) (D13.14.4E), cyclin D1 (92G2), cyclin B1 (D5C10), XIAP antibodies from Cell 
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Signalling Technologies. All antibodies were used at 1 : 500 dilutions except for actin (1 : 10 000), anti-
mouse and anti-rabbit (1 : 5000).
13. Annexin V/PI apoptosis assay. A2780 cells were seeded into Cellstar 12-well plates (Greiner Bio-
One) at a density of 20104 cells/well (1 mL per well). The cells were allowed to resume exponential 
growth for 24 h and subsequently they were exposed to HL2 and 2 at different concentrations for 24 h. 
After the supernatant solution was collected in 1.5 mL microtubes, the cells were washed with 100 μl of 
trypsin, which was combined with the supernatant. Subsequently, cells were trypsinized with 200 μl of 
trypsin for 5 min at 37 °C, 5% CO2, washed with 200 μl of PBS and combined with the supernatant. The 
cells were centrifuged at 2.5103 rpm for 5 min and the pellets were washed once with PBS and 
resuspended in 500 μl of Annexin V binding buffer and stained with Annexin V-FITC and PI reagents. 
The fluorescence was immediately analyzed by flow cytometry. The resulting dot blots were acquired 
from 10 000 events and quantified using Flowjo software (Flowjo LLC, Ashland, OR, USA).
14. Tyrosyl radical reduction in mouse R2 ribonucleotide reductase protein. The 9.4 GHz EPR 
spectra were recorded at 30 K on a Bruker EleXsys II E540 EPR spectrometer with an Oxford 
Instruments ESR900 helium cryostat, essentially as described previously.Error! Bookmark not defined. The 
small mouse R2 subunit without diferric-tyrosyl cofactor was produced from E.coli  carrying a mouse 
R2 cDNA plasmid. The cofactor was further regenerated, resulting in the formation of the cluster with 
0.38 tyrosyl radical/Fe(III) ratio, which is in agreement with the literature.41
15. Molecular docking calculations. The calculations were performed as described previously.20. The 
centre of the binding pocket was defined (x = 102.276, y = 87.568, z = 80.588)87 with 10 Å radius. The 
basic amino acids lysine and arginine were defined as protonated. Furthermore, aspartic and glutamic 
acids were assumed to be deprotonated. The GoldScore (GS),37 ChemScore (CS),88,89 Chem Piecewise 
Linear Potential (ChemPLP)90 and Astex Statistical Potential (ASP)90 scoring functions were 
implemented to validate the predicted binding modes and relative energies of the ligands using the 
GOLD v5.4 software suite. The parameter file for GS was augmented for Cu according to Sciortino et 
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al.38 The QikProp 4.691 and Marvin software package92 was used to calculate the molecular descriptors 
of the compounds. The reliability of QikProp is established for the molecular descriptors.93 
16. Bacterial Strains and antibacterial activity. Wild-type Pseudomonas aeruginosa PAO1 strain 
CECT 4122 (ATCC 15692) and Staphylococcus aureus CECT 86 (ATCC 12600) were obtained from the 
Spanish Type Culture Collection (CECT). All strains were routinely cultivated in TSB medium (Sharlab, 
Spain) at 37 ºC. Minimal inhibitory concentration (MIC) assays were determined by the microdilution 
method using TSB broth following the method described by the Clinical and Laboratory standards 
Institute.94 In brief, compounds were diluted in a 96-well microtiter plate (tissue culture-treated 
polystyrene; Costar 3595, Corning Inc., Corning, NY) to a final concentration ranging from 0.1 to 100 
µg/mL. A 100-µl aliquot of the bacterial suspension (around 5  105 colony forming units/mL 
(CFU/mL)) was inoculated, incubated at 37 ºC for 8 h at 150 rpm, and absorbance at 550 nm was read 
every 15 min in an Infinity 200 Pro microplate reader (Tecan). The MIC100 was determined as the lowest 
concentration that completely inhibited bacterial growth, and MIC50 in which bacterial growth was 
inhibited at 50%.
17. Bacterial viability test analysis. Cultures of S. aureus and P. aeruginosa were diluted in fresh TSB 
medium and grown overnight to the beginning of exponential phase (A550 0.3) and different compounds 
were added. After 3 h of incubation at 37 ºC in shaking conditions, cells were harvested and stained 
using the LIVE/DEAD BactLight Bacterial Viability Kit (Thermofisher) for 30 min. Fluorescent bacteria 
were visualized by a Nikon inverted fluorescent microscope ELIPSE Ti-S/L100 (Nikon) coupled with a 
DS-Qi2 Nikon camera.
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